CNTA vs. ITCI, ROIV, ASND, RVMD, LNTH, LEGN, NUVL, ELAN, CYTK, and BPMC
Should you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Nuvalent (NUVL), Elanco Animal Health (ELAN), Cytokinetics (CYTK), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.
Centessa Pharmaceuticals vs.
Intra-Cellular Therapies (NASDAQ:ITCI) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability, risk and community ranking.
Intra-Cellular Therapies has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.
Intra-Cellular Therapies received 492 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 67.84% of users gave Intra-Cellular Therapies an outperform vote while only 56.86% of users gave Centessa Pharmaceuticals an outperform vote.
Centessa Pharmaceuticals has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Centessa Pharmaceuticals' return on equity.
Intra-Cellular Therapies presently has a consensus price target of $97.23, indicating a potential upside of 15.75%. Centessa Pharmaceuticals has a consensus price target of $25.83, indicating a potential upside of 47.37%. Given Centessa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Centessa Pharmaceuticals is more favorable than Intra-Cellular Therapies.
In the previous week, Centessa Pharmaceuticals had 15 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 19 mentions for Centessa Pharmaceuticals and 4 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 1.06 beat Centessa Pharmaceuticals' score of 0.51 indicating that Intra-Cellular Therapies is being referred to more favorably in the media.
Intra-Cellular Therapies has higher revenue and earnings than Centessa Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Comparatively, 11.6% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Intra-Cellular Therapies beats Centessa Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Centessa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Centessa Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CNTA) was last updated on 12/24/2024 by MarketBeat.com Staff
